Daniel R Van Langenberg (Daniel Van Langenberg, Daniel R van Langenberg, Daniel van Langenberg)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 26

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

Journal of gastroenterology and hepatology

JGH open : an open access journal of gastroenterology and hepatology

Internal medicine journal

This page only lists publications with an associated author ORCID identifier.

Publications

Abhinav Vasudevan, Danny Con, Daniel R Van Langenberg
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply. Alimentary pharmacology & therapeutics 59 (6) (2024)
Abhinav Vasudevan, Danny Con, Daniel R Van Langenberg
Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply. Alimentary pharmacology & therapeutics 59 (8) (2024)
Natalie Yu, Tanya Lee, Daniel Tassone, Sara Vogrin, Steven Phan, Damien M Wu, Jason Zhang, Luke Wang, Jason Tjahyadi, Krishneel Dutt, Hana Liou, Chamara Basnayake, Emily Wright, Olga D Niewiadomski, Mark Lust, Julien Schulberg, Michael A Kamm, William Connell, Alexander J Thompson, Ida Hilmi, Raja A Raja Ali, Shu C Wei, Peter De Cruz, Antony B Friedman, Gregory T Moore, Daniel R Van Langenberg, Nik S Ding
6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy. Internal medicine journal (2024)
Abhinav Vasudevan, Danny Con, Daniel R Van Langenberg
Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply. Alimentary pharmacology & therapeutics 59 (8) (2024)
Abhinav Vasudevan, Danny Con, Daniel R Van Langenberg
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply. Alimentary pharmacology & therapeutics 59 (6) (2024)
Abhinav Vasudevan, Danny Con, Peter De Cruz, Miles Patrick Sparrow, Antony B Friedman, Mayur Garg, Soleiman Kashkooli, Peter R Gibson, Daniel R Van Langenberg
Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study). Alimentary pharmacology & therapeutics (2023)
Ashish Srinivasan, Peter De Cruz, Melissa Sam, Catherine Toong, Daniel R Van Langenberg
Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. Journal of gastroenterology and hepatology (2023)
Anuj Bohra, Diana Lewis, Jonathan P Segal, Abhinav Vasudevan, Daniel R Van Langenberg, Olga D Niewiadomski
Utility of panenteric capsule endoscopy for the detection of small-bowel Crohn's disease in patients with a normal magnetic resonance enterography: A prospective observational pilot study. JGH open : an open access journal of gastroenterology and hepatology 7 (12) (2023)
Ashish Srinivasan, Peter De Cruz, Melissa Sam, Catherine Toong, Daniel R Van Langenberg
Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. Journal of gastroenterology and hepatology (2023)
Anuj Bohra, Diana Lewis, Jonathan P Segal, Abhinav Vasudevan, Daniel R Van Langenberg, Olga D Niewiadomski
Utility of panenteric capsule endoscopy for the detection of small-bowel Crohn's disease in patients with a normal magnetic resonance enterography: A prospective observational pilot study. JGH open : an open access journal of gastroenterology and hepatology 7 (12) (2023)
Abhinav Vasudevan, Daniel R Van Langenberg
Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy. Alimentary pharmacology & therapeutics 55 (1) (2022)
Ashish Srinivasan, Daniel R Van Langenberg
Editorial: does anti-TNF "treatment persistence" always equate to "effective treatment"? Only objective disease assessments can answer the question. Alimentary pharmacology & therapeutics 54 (5) (2021)
Ayushi Chauhan, Ross Apostolov, Daniel R Van Langenberg, Mayur Garg
Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience - effective, safe, yet room for improvement. Internal medicine journal 51 (1) (2021)
Abhinav Vasudevan, Nina Parthasarathy, Danny Con, Steven Nicolaides, Ross Apostolov, Ayushi Chauhan, Maria Bishara, Raphael P Luber, Neetima Joshi, Anna Wan, James A Rickard, Tony Long, Declan Connoley, Miles Patrick Sparrow, Peter R Gibson, Daniel R Van Langenberg
Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Alimentary pharmacology & therapeutics 52 (7) (2020)
Ashish Srinivasan, Peter De Cruz, Daniel R Van Langenberg
Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Alimentary pharmacology & therapeutics 52 (3) (2020)
Abhinav Vasudevan, Daniel R Van Langenberg
Editorial: direct costs are only the tip of the iceberg in inflammatory bowel disease. Alimentary pharmacology & therapeutics 52 (5) (2020)
Ashish Srinivasan, Peter De Cruz, Daniel R Van Langenberg
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Alimentary pharmacology & therapeutics 52 (3) (2020)
Steven Nicolaides, Abhinav Vasudevan, Daniel R Van Langenberg
Letter: rationalising aminosalicylates in inflammatory bowel disease. Alimentary pharmacology & therapeutics 52 (10) (2020)
Abhinav Vasudevan, Danny Con, Steven Nicolaides, Daniel R Van Langenberg
Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply. Alimentary pharmacology & therapeutics 52 (9) (2020)
Ashish Srinivasan, Daniel R Van Langenberg, Robert D Little, Miles P Sparrow, Peter De Cruz, Mark G Ward
A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. Alimentary pharmacology & therapeutics 51 (12) (2020)
Satwik Motaganahalli, Lauren Beswick, Danny Con, Daniel R Van Langenberg
Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. Internal medicine journal 49 (1) (2019)
Daniel R Van Langenberg, Abhinav Vasudevan
Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Alimentary pharmacology & therapeutics 48 (9) (2019)
Dean Seah, Matthew C Choy, Alexandra Gorelik, William R Connell, Miles P Sparrow, Daniel R Van Langenberg, Geoffrey Hebbard, Gregory Moore, Peter De Cruz
Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. Journal of gastroenterology and hepatology 33 (1) (2018)
Matthew C Choy, Dean Seah, Alexandra Gorelik, Yoon-Kyo An, Cheng-Yu Chen, Finlay A Macrae, Miles P Sparrow, William R Connell, Gregory T Moore, Graham Radford-Smith, Daniel R Van Langenberg, Peter De Cruz
Predicting response after infliximab salvage in acute severe ulcerative colitis. Journal of gastroenterology and hepatology 33 (7) (2018)
Sally L James, Daniel R Van Langenberg, Kirstin M Taylor, Peter R Gibson
Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation). JGH open : an open access journal of gastroenterology and hepatology 2 (5) (2018)
Chu K Yao, Jacqueline S Barrett, Hamish Philpott, Alvin R T Chung, Daniel R Van Langenberg, Mayur Garg, Peter R Gibson
Poor predictive value of breath hydrogen response for probiotic effects in IBS. Journal of gastroenterology and hepatology 30 (12) (2016)